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Thoracic aortic dissection (AD) is one of the most common aortic emergencies. It can be fatal if not promptly
diagnosed and treated. Intramural hematoma (IMH) of the aorta is recognized as distinct from classic (double-barreled)
AD. IMH also frequently leads to aortic emergency, which can be fatal unless rapidly diagnosed and treated.
Recently, thoracic endovascular aortic repair (TEVAR) has been used for the treatment of complications caused by AD.
TEVAR is also a viable option for the treatment of complicated IHM. In this article, we review the details of TEVAR as
treatment options for AD and IMH, including the indications for TEVAR, imaging, and follow-up.
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Thoracic aortic diseases are life threatening. In the past, sur-
gical replacement was the only effective treatment, involving
operations that are technically complex and associated with
high-level morbidity (Garzon et al. 2005). Despite the signifi-
cant improvement of surgical techniques, anesthetic tech-
niques, and perioperative care, transthoracic aortic surgery
markedly reduces the risks of serious complications and
mortality (5–15% in elective cases and up to 50% in emer-
gent cases) (Ishida et al. 2004).
Numerous studies have reported the safety and effi-
cacy of thoracic endovascular aortic repair (TEVAR)
for various thoracic aortic diseases. The most common
thoracic aortic pathologic condition amenable to TEVAR
is aortic aneurysm, but aortic dissection (AD) has been in-
dicated for TEVAR. Recently, many reports show that
TEVAR has been used for the treatment of complications
caused by AD (Garzon et al. 2005; Dake et al. 1999).
Intramural hematoma (IMH) of the aorta is now recog-
nized as distinct from AD (Dake 2004). In IMH, ulcer-like
projections (ULPs) are also identifiable during follow-up
and may be considered as a new intimal disruption (Kitai
et al. 2010). Numerous reports on IMH (Sueyoshi et al.
2002) have suggested that ULPs can progress to aneurysms* Correspondence: sueyo@nagasaki-u.ac.jp
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the treatment of complicated IMH patients, however, re-
mains controversial.
This article presents TEVAR for complicated AD and
IMH and serial CT changes following TEVAR. In this
article, we review the details of TEVAR for complicated
AD and IMH, including the indications for TEVAR, im-
aging, and follow-up.Endovascular repair strategy for patients with AD or IMH
Usefulness of TEVAR for AD
When TEVAR is conducted for AD, aortic stability is
promoted by thrombosis of the false lumen and stent-
induced expansion of the true lumen, and it mimics the
healing process (Garzon et al. 2005). Incomplete closure
at the entry site and nonclotting of the false lumen may
be predictors of a poor prognosis following TEVAR
(Czermak et al. 2000). However, TEVAR may still be of
merit because it may prevent the false lumen from enlar-
ging, because a high blood pressure is no longer trans-
mitted from the aorta through a large primary tear in
the intima (Dake et al. 1999).
Stent-graft placement over the entry site leads to the
resumption of normal blood flow in the true lumen and
causes false lumen thrombosis (Garzon et al. 2005; Dake
et al. 1999; Vedantham et al. 2003). This can cause vis-
ceral ischemia if any major branch vessels are supplieds an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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taneous balloon fenestration, branch vessel stent place-
ment, or aortic stent placement should be conducted in
such cases (Garzon et al. 2005; Vedantham et al. 2003).
Potential indication of TEVAR for Stanford type A AD or IMH
The management of acute type A AD or type A IMH is
life-saving, emergent open surgery. Graft replacement of
the ascending aorta, with or without aortic valve repair
or replacement is often involved.
TEVAR indications are very limited for type A AD and
IMH: (Garzon et al. 2005) retrograde DeBakey type III AD,
and (Ishida et al. 2004) residual AD or IMH with complica-
tions after surgery. The two above-mentioned conditions
can be treated by TEVAR, and a previous report showed that
the outcomes are good (Tang and Dake 2009). However, fa-
vorable accumulated evidence for TEVAR is insufficient.
Further studies are therefore needed (Tang and Dake 2009).
Potential indication of TEVAR for Stanford type B AD
The majority of patients with Stanford type B dissection
have received medical therapy (Dake et al. 1999). Those
with complications typically undergo emergency surgery
(Dake et al. 1999). However, both surgical and medical
management (blood pressure and heart rate control) some-
times lead to unfavorable outcomes. Patients who have re-
ceived medical therapy currently show a mortality rate of
about 20% (Dake et al. 1999). The mortality rate in surgical
repair cases is about 35%, and above 50% for surgical cases
involving end-organ ischemia (Dake et al. 1999).
TEVAR has emerged as a less invasive option with low
periprocedural mortality and morbidity, particularly for the
elderly with serious concomitant illnesses. The 30-day mor-
tality rates are less than 10%, with mortality typically occur-
ring in only those patients with acute presentation and
ischemia of organs. These patients show the highest risk
for all types of surgical intervention (Garzon et al. 2005).
Regarding TEVAR for AD, type B AD should be di-
vided into two major groups: complicated and uncom-
plicated type B ADs. Complicated dissection is noted in
about 30% of patients who present with acute type B
aortic dissection (Criado 2011). Complicated AD refers
to evidence of thoracic aortic rupture (hematoma and so
on outside aortic wall), malperfusion (ischemia involving
the viscera, kidneys, spinal cord, or lower extremities),
or rapid expansion in the distal arch or proximal de-
scending aorta to an overall aortic diameter of 4.5 cm or
more. Such findings necessitate intervention, as they im-
mediately threaten patient’s lives or limbs (Criado 2011).
Here, we divided type B AD into 4 types based on the
therapeutic strategy: 1) acute (within 2 weeks of the ini-
tial event) uncomplicated AD, 2) acute complicated AD,
3) chronic (more than 2 weeks from the initial event)
uncomplicated AD, and 4) chronic complicated AD.Acute complicated and chronic complicated type B ADs
can be treated with TEVAR. A previous study reported
favorable outcomes (Parsa et al. 2010).
A subset of higher-risk patients may be present with
uncomplicated ADs who have the potential to benefit
from TEVAR. TEVAR in addition to optimal medical
treatment is associated with improved 5-year aorta-
specific survival rates and delayed disease progression in
uncomplicated AD patients. In the presence of stable
type B dissection with suitable anatomy, we should
consider preemptive TEVAR to improve the late out-
comes (Nienaber et al. 2013). Before scaffolding be-
come widely accepted, asymptomatic patients at risk
with a partial false critical lumen diameter, lumen
thrombosis, or a large entry tear should be considered
for TEVAR (Nienaber et al. 2013).
Covering the entry site in acute AD may lead to the total
regression of the false lumen, and so few additional
complete therapeutic procedures may be required (Figure 1).
Alternatively, in chronic AD, the false lumen may be par-
tially thrombosed and the intima is more rigid, and so exclu-
sion of the flow into the false lumen causes thrombosis and
partial false lumen shrinkage (Garzon et al. 2005) (Figure 2).
Indications of TEVAR for type B IMH
IMH-related mortality in patients with involvement of
the ascending aorta has been considered to be similar to
that of AD. Early surgical repair is standard treatment
for such patients (Dake 2004). Asymptomatic patients
with descending aorta involvement can be monitored
closely while undergoing treatment, with intervention
only for patients who developing complications such
as persistent pain, complicated ULP, signs of impend-
ing rupture, progressive maximal aortic wall thick-
ness and compression of the true lumen, an enlarging
aorta, or the compromising of a major arterial branch
(Dake 2004).
Conventional open surgical repair is associated with
high level of morbidity and mortality, particularly in pa-
tients who generally are not ideal surgical candidates be-
cause they are of an advanced age and/or have coexisting
diseases. The 30-day mortality rates after open surgery re-
portedly range from 10 to 50% (Dake 2004). Less invasive
strategies involving the endovascular placement of stent-
grafts for the IMH covering have recently been examined.
In type B IMH, patients with complications, such as
redissection and complicated ULP, may be treated by
TEVAR. Recent studies have revealed that TEVAR yields
favorable clinical outcomes (Eggebrecht et al. 2009).
ULPs are sites of intimal disruption. Lesions can show
progression to both aneurysms and localized AD. In
IMH patients, new lesions or complications may sub-
sequently develop, including ULP, classic AD, or rup-
ture. Recent studies showed that even very early stage
Figure 1 A 72-year-old male with type B acute AD. A. One month after onset, contrast-enhanced CT image shows progressive dilatation of
the false lumen. B. Aortography shows the entry in the descending aorta (arrow). TEVAR (GORE TAG: 34-mm diameter & 20-cm length) was conducted
to close the entry. C. One week after endovascular treatment, CT image shows thrombosed false lumen. D. Two months after endovascular treatment,
contrast-enhanced CT image shows that the false lumen has markedly decreased.
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differ from penetrating atherosclerotic ulcers (PAUs),
but their differentiation may be impossible in some pa-
tients (Sueyoshi et al. 2002).
Reportedly, complicated ULPs include: (Garzon et al.
2005) progressive aneurysmal dilatation (size of aorta
with ULP more than 1.5 times normal) and/or (Ishida
et al. 2004) ULP rupture. TEVAR is generally reserved for
patients typically categorized as poor open repair candi-
dates. TEVAR has been viewed as optimal for complicated
ULPs in patients with type B IMH if anatomically applic-
able, while open surgery has been employed for non-
endovascular treatment candidates (Sueyoshi et al. 2014).
The verification of the short-term safety and efficacy
of TEVAR has expanded its application to diverse thor-
acic aortic pathologies; however, no generally accepted
therapeutic regimen has been established for compli-
cated ULPs. Further studies are therefore necessary.
TEVAR for complicated ULP and serial changes of imaging
findings after TEVAR
Fate of complicated ULP and IMH after TEVAR
In a prior study, TEVAR is a useful treatment for compli-
cated ULPs in patients with IMH. TEVAR also promotesoptimal remodeling of the affected aorta. ULP closure by
TEVAR is related to hematoma resorption of the affected
aorta by IMH. ULP may provide arterial pressure or blood
flow to the false lumen. If TEVAR closes the ULP, arterial
pressure or blood flow of the false lumen is reduced or
stopped. This may facilitate optimal remodeling of the
affected aorta (Sueyoshi et al. 2014). TEVAR can be
viewed as an effective alternative to open surgery.
Long-term follow-up, however, is necessary to investi-
gate the durability of both the device and TEVAR
within the thoracic aorta.
Complications after TEVAR for AD and IMH
The mid-term outcomes of TEVAR in chronic type B AD
patients were presented in several reviews. The technical
success rate was 89.9%. Mid-term mortality was 9.2% and
survival rates ranged from 59.1 to 100% in studies with a
median follow-up of 24 months. A total of 8.1% of patients
developed endoleak, (type I predominance).
Concerning complications after TEVAR for AD, acute
major complications included stroke, 3.1%; conversion to
type A dissection, 2%; paraplegia, 1.9%; bowel infarction,
0.9%; and major amputation, 0.2% (Figure 3). Aortic rupture
was reported at a rate of 0.8% (Thrumurthy et al. 2011).
Figure 2 A 78-year-old female with type B chronic AD. A. Six years after onset, contrast-enhanced CT image shows aneurysmal dilation of the
affected aorta and entry site (arrow). B, C. TEVAR (GORE TAG: 37-mm diameter & 20-cm length) was performed. Contrast-enhanced CT image and
3D CT angiography show that the entry site was closed. D, E. Six (F) and (G) 15 months after TEVAR, contrast-enhanced CT images show that the
false lumen has partially thrombosed, but aneurysmal dilation of the affected aorta remains.
Figure 3 An 81-year-old female with type B chronic AD. A-C. One year after onset, oblique sagittal MPR images and aortography show
aneurysmal dilation of the affected aorta. D. TEVAR (handmade stent-graft: 38-mm diameter & 20-cm length) was performed the entry site was
closed. E. Three months after TEVAR, 3D CT angiography shows a type A AD due to a new intimal tear caused by the proximal edge of the stent-graft.
Ascending aorta replacement was conducted. F. Three months after surgery, 3D CT angiography shows a type B AD due to a new intimal tear caused by the
distal edge of the stent-graft. G. Re-TEVAR (GORE TAG: 37-mm diameter & 20-cm length × 2) was performed. 3D CT angiography images show that false
lumen fully thrombosed.
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ranged from 0 to 60% in studies with a median follow-up
of 31 months. Of the patients, 7.8% developed aneurysms
of the distal aorta or continued false lumen perfusion withFigure 4 An 87-year-old female with type B acute intramural hemato
TAG: 37-mm diameter & 20-cm length) was performed because of ULP enl
chest pain. Unenhanced CT images show a mediastinal hematoma (arrow)
(small pseudoaneurysm: arrows) due to the edge of the stent-graft was no
performed to close a SINE tear. F. Three months after re-TEVAR, a SINE tearaneurysmal dilatation. Aorto-esophageal fistula, delayed
retrograde type A dissection, and neurological complica-
tions developed as rare complications (paraplegia, 0.45%;
stroke, 1.5%) (Thrumurthy et al. 2011).ma of the aorta (IMH). One month later form onset, TEVAR (GORE
argement. A, B. One year after TEVAR, this patient complained of severe
. C-E. Contrast-enhanced CT and MIP images show that a SINE tear
ted. Re-TEVAR (GORE TAG: 37-mm diameter & 20-cm length × 2) was
and mediastinal hematoma disappeared.
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type B IMH have not been completely unknown. In two
of previously reported 18 patients, aortic injury (11%)
additionally occurred during follow-up, diagnosed by
CT. One patient had retrograde AD 2 years after
TEVAR. One patient showed pseudonauerysm develop-
ment 6 months after TEVAR. Additional endovascular
treatment and pseudonauerysm repair were performed
(Sueyoshi et al. 2014).
Stent graft-induced new entry (SINE) tear
Stent graft-induced new entry (SINE) tear developed ei-
ther perioperatively or during follow-up. The definition
of SINE was a new intimal tear caused by the stent graft
itself, excluding those resulting from natural disease pro-
gression or iatrogenic injury due to endovascular ma-
nipulation. In a previous report, proximal and distal
SINE represented SINE at proximal and distal ends of
the endograft, respectively. Incidence and mortality rates
reached 3.4 and 26.1%, respectively.
Proximal SINEs are noted at the greater curve of the
arch and they cause retrograde type A dissection. The in-
cidence of SINE was 33.3% among Marfan patients vs.
3.26% among non-Marfan patients (P = 0.016) (Dong et al.
2010). Radiologists should be aware that SINE tears can
develop in IMH patients as late complications (Figure 4).
Conclusions
Endovascular techniques have recently been emerging as
an alternative treatment for AD or IMH. They constitute
a less invasive therapeutic option compared to standard
surgery, even when patients have associated diseases that
make them poor surgical candidates.
TEVAR’s role in the treatment of AD and IMH re-
mains controversial. However, TEVAR may be a suitable
option for the treatment of complicated AD and IHM.
TEVAR may contribute to close complicated ULPs and
facilitate ideal remodeling of the affected aorta.
Based on our experience, this technique is an effective
alternative to open surgery. However, long-term follow-
up is required to assess the durability of the device and
repair following TEVAR.
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